• 한국생물공학회:학술대회논문집
• /
• 한국생물공학회 2005년도 생물공학의 동향(XVII)
• /
• pp.415-416
• /
• 2005

• 한국생물공학회:학술대회논문집
• /
• 한국생물공학회 2005년도 생물공학의 동향(XVII)
• /
• pp.424-425
• /
• 2005

• 한국잠사학회:학술대회논문집
• /
• 한국잠사학회 2003년도 제46회 춘계 학술연구 발표회
• /
• pp.40-40
• /
• 2003

Recombinant plasmids harboring heterologous genes coding enhanced green fluorescent protein (EGFP) and erythropoietin (EPO) were transfected and expressed in Drosophila melanogaster S2 cells. Stably transformed cell populations expressing EGFP or monkey EPO were isolated after 4 weeks of selection with hygromycin B. (omitted)

• Toxicological Research
• /
• 제21권3호
• /
• pp.227-234
• /
• 2005

• 한국임상약학회지
• /
• 제21권2호
• /
• pp.122-130
• /
• 2011

Objective: Although recombinant human erythropoietin (rhEPO) has revolutionized the treatment of anemia in chronic kidney disease (CKD) receiving hemodialysis (HD) with no need of blood transfusion, some patients have a blunted or appear to be resistant to rhEPO. There is a controversy in the causes of rhEPO resistance in maintenance HD patients with anemia. This study is to examine current anemia treatment outcomes and the factors influencing the rhEPO responsiveness in HD patient with CKD. Methods: The clinical parameters or factors relating to erythrompoietin treatment outcomes and erythropoietin responsiveness were collected from the HD patients in two large dialysis centers for three months. The collected paramenters included serum iron, total iron biding capacity (TIBC), transferrin saturation rate, ferritin, albumin, intact PTH, C-reactive protein (CRP), nPCR and medications such as an angiotensin converting enzyme inhbitor, an angiotension II receptor blocker and an HMG-CoA reductase inhibitor (HMG-CoA RI). The data were analyzed to examine the degree of acheiveing the anemia treatment goal and factors relating to ERI. Results: Among total 111 patients, 42 (42.3%) and 47 (37.8%) patients achieved the target Hct and Hb based on the Health Insurance Review and Assessment Services (HIRA) reimbursement criteria. In the higher ERI group (upper quartile), the patients had higher CRP levels (0.5 mg/dl) (p=0.0096), and lower TIBC score (<$240{\mu}g/dl$) (p=0.0027), and less patients were taking HMG-CoA RI (p=0.0019). Male patients (p=0.0204), patients with high TIBC score ($R^2$=0.084, p=0.0021) and patients taking HMG-CoA RI (p=0.0052) required to administer less dose of rhEPO meaning higher erythropoietin responsiveness. Conclusion: Less than 50% of CKD patients were achieving the goals of anemia by erythropoietin administration in large hospitals in Korea even though the goals were lower than those of NKF-K/DOQI practice guideline. The factors influencing ERI were sex, TIBC and HMG-CoA RI administration status, and neither an ACEI nor an ARB did not influence ERI.

• 한국생물공학회:학술대회논문집
• /
• 한국생물공학회 2002년도 생물공학의 동향 (X)
• /
• pp.265-268
• /
• 2002

Lactate and ammonia are two major toxic waste products formed during mammalian cell culture. Accumulation of the side products have negative effects of on cell growth and specific production rate. In this study, K-562 cells were used as the host cell of a recombinant protein. Effects of carbon sources were invetigated focused on the cell culture span, the accumulation of lactate and ammonia in culture of recombinant K-562 cells.

• KSBB Journal
• /
• 제11권3호
• /
• pp.288-294
• /
• 1996

CHO 세포를 0.5%, 1 %. 2%, 3%, 4% 및 5% 놓도의 FBSd를 함유한 MEMa 배지에 $1{\times}10^4cells/\textrm{cm}^2 와 2{\times}10^4cells/\textrm{cm}^2$의 초기 농도로 정치배양하여 세포 성장과 EPO 생산 특성을 조사하였다. 혈청 농도와 접종 농도를 증가시킴에 따라 세포 증식 속도와 최대 세포 농도가 증가하는 경향을 보였으며, 적절한 혈청 농도의 선택이 세포 성장의 최적화에 필 요하다고 할 수 있다. 세포 성장 도중에 무혈청배지로 교환한 결과 세포 성장과 EPO 생산이 증가되었다. 배지를 교환하지 않았을 경우 세포 성장이 최대 ($2.1{\times}10^5cells/\textrm{cm}^2$)에 도달된 후 급격히 세포농도가 감소하는 높은 사멸율을 보이고, EPO의 최대 농도 도 2,380units/mL에 불과하였으나, 무혈청배지로 교환한 배양에서는 세포 성장이 크게 증가하여 $6.2{\times}105cells/$\textrm{cm}^2$의 최대 세포농도와 7,470units/mL 의 EPO 농도를 얻었다. 따라서 CHO 세포 성장과 E EPO 생산과는 상호 연관이 있으며, 세포배양으로 EPO 생산을 극대화하기 위해서는 CHO 세포의 고 농도 배양이 필요하다고 할 수 있다.

• Journal of Microbiology and Biotechnology
• /
• 제23권5호
• /
• pp.699-706
• /
• 2013

We have previously reported that N-acetylcysteine (NAC) not only delayed apoptosis but also enhanced the production of recombinant erythropoietin (EPO) in Chinese hamster ovary (CHO) cell culture. To investigate the production enhancement mechanism, the effects of similar thiol-reducing agents were studied. Intriguingly, all mild reducing agents examined including mercaptoethanesulfonic acid (MESNA), thiolactic acid (TLA), and thioglycolate (TG) were shown to block apoptosis and increase EPO production. A pulse-chase study of EPO secretion revealed that all four thiol-reducing agents increased the EPO secretion rate; among them TLA showed the highest rate. In terms of product quality, the sialic acid content of the glycoprotein is one of the most important factors. It was reported that a number of glycoproteins produced by CHO cells often have incomplete sialylation, particularly under high-producing conditions. Human ${\alpha}2,3$-sialyltransferase (${\alpha}2,3$-ST) was introduced into EPO-producing CHO cells in order to compensate for the reduced sialylation during supplementation with NAC. When ${\alpha}2,3$-ST was expressed in the presence of NAC, reduced sialylation was restored and an even more sialylated EPO was produced. Thus, our study is significant in that it offers increased EPO production while still allowing the prevention of decreased sialylation of EPO.

• Biomolecules & Therapeutics
• /
• 제10권1호
• /
• pp.59-69
• /
• 2002

Recently, recombinant human erythropoietin (rHu-EPO) has been used to treat various types of anemia. YHB216 is a new rHu-EPO developed by Yuhan Research Institute. In this study, we investigated the single dose and 4-week repeated dose toxicity of YHB216 in Beagle dogs. In the single dose toxicity study, YHB216 was administered intravenously at single dose levels of 0 and 25,000 IU/kg to dogs (2 dogs/sex/group). There were no treament-related changes in survivals, clinical signs, body weight gain, hematological values, blood chemical values, and necropsy finding during experimental period. In the repeated dose toxicity study, YHB216 was administered intravenously to dogs for 4 weeks at the dose levels of 0, 100, 500, and 2,500IU／kg (3 dogs/sex／group). There were no toxicologically significant changes in clinical signs, body weights, food and water consumptions, ophthalmoscopy, urinalysis and blood chemistry. There were increased values of red blood cell, hemoglobin, and hematocrit at all treated groups. Spleen revealed increased weight and extramedullary hematopoiesis at 500 IU/kg or more. These changes are all considered to be Pharmacology-related effects and were recovered after 4-week recovery period. From these results, it is concluded that LD50 value was above 25,000 IU/kg in the single dose toxicity study of YHB216 in dogs and the no observed adverse effect level (NOAEL) was 100 IU/kg day in the repeated dose toxicity study of YHB216 in dogs.

• Molecules and Cells
• /
• 제38권6호
• /
• pp.496-505
• /
• 2015

A variant peak was detected in the analysis of RP-HPLC of rHu-EPO, which has about 7% relative content. Fractions of the main and the variant peaks were pooled separately and further analyzed to identify the molecular structure of the variant peak. Total mass analysis for each peak fraction using ESI-TOF MS shows differences in molecular mass. The fraction of the main peak tends to result in higher molecular masses than the fraction of the variant. The detected masses for the variant are about 600-1000 Da smaller than those for the main peak. Peptide mapping analysis for each peak fraction using Asp-N and Glu-C shows differences in O-glycopeptide profiles at Ser126. The O-glycopeptides were not detected in the fraction of the variant. It is concluded that the variant peak is non-O-glycosylated rHu-EPO and the main peak is fully O-glycosylated rHu-EPO at Ser126.